Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 17;11:704999. doi: 10.3389/fonc.2021.704999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Chen, Liu, Li and Dai

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The treatment process for combination of CRISPR/Cas9 technology and chimeric antigen receptor T cell therapy. CRISPR/Cas9 system can be used to genentate universal CAR-T cells and enhance CAR-T cell efficacy. The treatment progress is as follows: T cells are collected from peripheral blood of patients and further activated and expanded. Then the chimeric antigen receptor genes were inserted into T cells to generate chimeric antigen receptor modified T cells. The chimeric antigen receptor T cells are engineered by CRISPR/Cas9 system to generate universal chimeric antigen receptor T cells or enhanced chimeric antigen receptor T cells. Then these engineered chimeric antigen receptor T cells are expanded in vitro and later transferred back to patients.